OpenAI AI Agents Bypassed UN Website Controls in Data Scraping 
BlackRock’s Rick Rieder Favors Bonds Over Stocks as Treasury Yields Surge 
Chainlink Launches CCIP 2.0 With Enhanced Cross-Chain Security 
Europe’s AI Data Centre Boom Strengthens Case for Nuclear Power 
Oura IPO Draws Strong Demand Ahead of $2.2 Billion Offering 
OpenAI Agents Access U.S. Government Websites During Testing 
OpenAI, Anthropic CEOs Summoned to Australia AI Inquiry 
Oil Prices Jump Nearly 3% as Iran Holds Firm on Hormuz Conditions 
UK PM Burnham to Unveil Economic Vision at Labour Conference 
AMD Hits $1 Trillion as BofA Raises Price Target to $720 
Morgan Stanley Raises TD Synnex Price Target to $359 on Strong AI Demand 
Japan Warns Markets Over Yen Weakness 
Oil Prices Rise as Iran Holds Firm on Strait of Hormuz Deal 
XRP Price Targets $1.70 as Bullish Momentum Builds 
Nissan Targets US Hybrid Growth With Rogue e-Power Launch 
ECB May Stop Rate Hikes After December, Capital Economics Says 
Asian Stocks Fall as Oil Surge, Bond Yields and AI Concerns Hit Markets 
Add as a preferred source on Google
SK Plasma Co. Ltd. is building a new blood product plant with an investment of KRW300 billion or about $250 million. The facility is set to be constructed in Indonesia.
Once in full operation, the new plant is expected to have the capacity to produce one million liters of blood products per year. SK Plasma will break ground some time this year, and the plant will be completed in two years.
Business insiders revealed earlier this week that the South Korean firm that produces albumin, immunoglobulin, coagulation factors, and antithrombin received the final approval for the construction of its plant from the Ministry of Health and Welfare of Indonesia not long ago. The facility will process the collected blood plasma and turn them into therapeutic agents.
Business Korea reported that for this project, SK Plasma would partner with Infion through a joint venture (JV) agreement. It is an Indonesian pharmaceutical company that will SK Plasma with its business operation in the country.
The size of the company’s upcoming plant in Indonesia is said to have a bigger production capacity than its facility in Andong, South Korea. It will offer 1.6 times more than the 600,000-liter capacity of its Korean plant.
In any case, the new factory will produce six types of blood products like Liv Gamma and albumin. The Korea Herald reported that albumin and immune globulin, which will be produced at the SK Plasma Indonesian facility, are typically used for patients with hemophilia and immunodeficiency diseases. These are made through strict and rigorous processes, including the centrifugation of blood collected from blood donation drives.
The blood products will ensure a stable supply in Indonesia, where the population is already close to 300 million. It was said that 100% of the citizens are currently dependent on imports of blood products.
“By transferring technologies relating to blood products and installing a manufacturing facility in a country that has no related infrastructure, SK Plasma seeks to create new business opportunities and reach the company’s ESG goals,” Kim Seung Joo, SK Plasma’s chief executive officer, said in a statement.
